Chi-Med Signs Collaboration With Lilly For Oncology, Inflammation Candidates
This article was originally published in PharmAsia News
Executive Summary
Chi-Med's wholly owned research and development subsidiary Hutchison MediPharma will collaborate with Eli Lilly on the discovery and development of pharmaceutical targets in oncology and inflammation, Chi-Med announced Aug. 20
You may also be interested in...
Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News
Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News
Eli Lilly In Asia Expansion Overdrive
SHANGHAI - Eli Lilly opened a brand new Asian office and unveiled a major expansion at a second office in as many days as part of a company-wide shift to a new collaborative research and development model, company officials told PharmAsia News